Recognition of Class II MHC Peptide Ligands That Contain β-Amino Acids

Key Points Peptides with β-amino acids can bind tightly to MHC-II and activate TCR signaling. Incorporation of β-amino acids enhances resistance to degradation by protease(s). A selected β-amino acid–containing peptide stimulated T cells in mice. Proteins are composed of α-amino acid residues. This consistency in backbone structure likely serves an important role in the display of an enormous diversity of peptides by class II MHC (MHC-II) products, which make contacts with main chain atoms of their peptide cargo. Peptides that contain residues with an extra carbon in the backbone (derived from β-amino acids) have biological properties that differ starkly from those of their conventional counterparts. How changes in the structure of the peptide backbone affect the loading of peptides onto MHC-II or recognition of the resulting complexes by TCRs has not been widely explored. We prepared a library of analogues of MHC-II–binding peptides derived from OVA, in which at least one α-amino acid residue was replaced with a homologous β-amino acid residue. The latter contain an extra methylene unit in the peptide backbone but retain the original side chain. We show that several of these α/β-peptides retain the ability to bind tightly to MHC-II, activate TCR signaling, and induce responses from T cells in mice. One α/β-peptide exhibited enhanced stability in the presence of an endosomal protease relative to the index peptide. Conjugation of this backbone-modified peptide to a camelid single-domain Ab fragment specific for MHC-II enhanced its biological activity. Our results suggest that backbone modification offers a method to modulate MHC binding and selectivity, T cell stimulatory capacity, and susceptibility to processing by proteases such as those found within endosomes where Ag processing occurs.

[1]  S. Gellman,et al.  Receptor selectivity from minimal backbone modification of a polypeptide agonist , 2018, Proceedings of the National Academy of Sciences.

[2]  H. Ploegh,et al.  Nanobody–Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses , 2018, Cancer Immunology Research.

[3]  H. Ploegh,et al.  Targeted antigen delivery by an anti-class II MHC VHH elicits focused αMUC1(Tn) immunity† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc00446j Click here for additional data file. , 2017, Chemical science.

[4]  H. Ploegh,et al.  Generation of Immunity against Pathogens via Single-Domain Antibody–Antigen Constructs , 2016, The Journal of Immunology.

[5]  P. Sexton,et al.  β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues. , 2016, Journal of the American Chemical Society.

[6]  S. Gellman,et al.  Targeting recognition surfaces on natural proteins with peptidic foldamers. , 2016, Current opinion in structural biology.

[7]  Allison S. Walker,et al.  In Vivo Biosynthesis of a β-Amino Acid-Containing Protein. , 2016, Journal of the American Chemical Society.

[8]  W. S. Horne,et al.  Peptide Backbone Composition and Protease Susceptibility: Impact of Modification Type, Position, and Tandem Substitution , 2016, Chembiochem : a European journal of chemical biology.

[9]  S. Gellman,et al.  Targeting diverse protein–protein interaction interfaces with α/β-peptides derived from the Z-domain scaffold , 2015, Proceedings of the National Academy of Sciences.

[10]  J. Sidney,et al.  Consequences of Periodic α-to-β3 Residue Replacement for Immunological Recognition of Peptide Epitopes , 2015, ACS chemical biology.

[11]  D. D. Da Silva,et al.  Functional analysis of HPV-like particle-activated Langerhans cells in vitro. , 2015, Methods in molecular biology.

[12]  P. Perlmutter,et al.  Single β3-amino acid substitutions to MOG peptides suppress the development of experimental autoimmune encephalomyelitis , 2014, Journal of Neuroimmunology.

[13]  A. Saghatelian,et al.  A Potent α/β-Peptide Analogue of GLP-1 with Prolonged Action in Vivo , 2014, Journal of the American Chemical Society.

[14]  S. Gellman,et al.  Backbone modification of a polypeptide drug alters duration of action in vivo , 2014, Nature Biotechnology.

[15]  Carla P. Guimarães,et al.  Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions , 2013, Nature Protocols.

[16]  Peter Cresswell,et al.  Pathways of antigen processing. , 2013, Annual review of immunology.

[17]  Clemencia Pinilla,et al.  Measurement of MHC/Peptide Interactions by Gel Filtration or Monoclonal Antibody Capture , 2013, Current protocols in immunology.

[18]  S. Gellman,et al.  NINETEEN a-Helix Mimicry with a / b-Peptides , 2013 .

[19]  S. Gellman,et al.  α-Helix mimicry with α/β-peptides. , 2013, Methods in enzymology.

[20]  L. Stern,et al.  Conformational variation in structures of classical and non‐classical MHCII proteins and functional implications , 2012, Immunological reviews.

[21]  J. Maynard,et al.  Flanking Residues Are Central to DO11.10 T Cell Hybridoma Stimulation by Ovalbumin 323–339 , 2012, PloS one.

[22]  W Seth Horne,et al.  Peptide and peptoid foldamers in medicinal chemistry , 2011, Expert opinion on drug discovery.

[23]  Ida E. Andersson,et al.  (E)-alkene and ethylene isosteres substantially alter the hydrogen-bonding network in class II MHC A(q)/glycopeptide complexes and affect T-cell recognition. , 2011, Journal of the American Chemical Society.

[24]  S. Gellman,et al.  Broad distribution of energetically important contacts across an extended protein interface. , 2011, Journal of the American Chemical Society.

[25]  N. Croft,et al.  Peptidomimetics: modifying peptides in the pursuit of better vaccines , 2011, Expert review of vaccines.

[26]  Min Lu,et al.  Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers , 2009, Proceedings of the National Academy of Sciences.

[27]  Robert M. Plenge,et al.  Defining the Role of the MHC in Autoimmunity: A Review and Pooled Analysis , 2008, PLoS genetics.

[28]  W Seth Horne,et al.  Sequence-based design of alpha/beta-peptide foldamers that mimic BH3 domains. , 2008, Angewandte Chemie.

[29]  Bjoern Peters,et al.  HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.

[30]  H. Gruppen,et al.  Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. , 2007, Journal of agricultural and food chemistry.

[31]  E. Unanue,et al.  The Insulin-Specific T Cells of Nonobese Diabetic Mice Recognize a Weak MHC-Binding Segment in More Than One Form1 , 2007, The Journal of Immunology.

[32]  S. Muller,et al.  Heteroclitic properties of mixed α-and aza-β3-peptides mimicking a supradominant CD4 T cell epitope presented by nucleosome , 2007 .

[33]  S. Muller,et al.  Heteroclitic properties of mixed alpha- and aza-beta3-peptides mimicking a supradominant CD4 T cell epitope presented by nucleosome. , 2007, Molecular immunology.

[34]  Heinrich Leonhardt,et al.  Targeting and tracing antigens in live cells with fluorescent nanobodies , 2006, Nature Methods.

[35]  J. McCluskey,et al.  T Cell Determinants Incorporating β-Amino Acid Residues Are Protease Resistant and Remain Immunogenic In Vivo1 , 2005, The Journal of Immunology.

[36]  A. Sant,et al.  Energetics and cooperativity of the hydrogen bonding and anchor interactions that bind peptides to MHC class II protein. , 2005, Journal of molecular biology.

[37]  E. Bergseng,et al.  Main Chain Hydrogen Bond Interactions in the Binding of Proline-rich Gluten Peptides to the Celiac Disease-associated HLA-DQ2 Molecule* , 2005, Journal of Biological Chemistry.

[38]  P. Kast,et al.  The Proteolytic Stability of ‘Designed’ β‐Peptides Containing α‐Peptide‐Bond Mimics and of Mixed α,β‐Peptides: Application to the Construction of MHC‐Binding Peptides , 2005 .

[39]  M. Wauben,et al.  Possibilities and limitations in the rational design of modified peptides for T cell mediated immunotherapy. , 2005, Molecular immunology.

[40]  M. Patarroyo,et al.  Characterization of a reduced peptide bond analogue of a promiscuous CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1. , 2004, Molecular immunology.

[41]  P. Perlmutter,et al.  β-amino acids: Versatile peptidomimetics , 2002 .

[42]  H. Ploegh,et al.  Specific role for cathepsin S in the generation of antigenic peptides in vivo , 2002, European journal of immunology.

[43]  P. Perlmutter,et al.  Beta-amino acids: versatile peptidomimetics. , 2002, Current medicinal chemistry.

[44]  A. Sant,et al.  Hydrogen Bond Integrity Between MHC Class II Molecules and Bound Peptide Determines the Intracellular Fate of MHC Class II Molecules1 , 2001, The Journal of Immunology.

[45]  C. Beeson,et al.  Utility of azapeptides as major histocompatibility complex class II protein ligands for T-cell activation. , 2001, Journal of medicinal chemistry.

[46]  A. Sant,et al.  Energetic asymmetry among hydrogen bonds in MHC class II⋅peptide complexes , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Rognan,et al.  β-Amino Acid Scan of a Class I Major Histocompatibility Complex-restricted Alloreactive T-cell Epitope* , 2001, The Journal of Biological Chemistry.

[48]  J. Briand,et al.  Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART‐1 protein , 2001, Journal of peptide science : an official publication of the European Peptide Society.

[49]  J. Briand,et al.  Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes. , 2000, Journal of medicinal chemistry.

[50]  R Crowther,et al.  Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. , 2000, Journal of medicinal chemistry.

[51]  B. Chain,et al.  Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation. , 2000, Seminars in Cell and Developmental Biology.

[52]  B. Evavold,et al.  DO11.10 and OT-II T Cells Recognize a C-Terminal Ovalbumin 323–339 Epitope1 , 2000, The Journal of Immunology.

[53]  H. Ploegh,et al.  Proteolysis in MHC class II antigen presentation: who's in charge? , 2000, Immunity.

[54]  B. Evavold,et al.  DO 11 . 10 and OT-II T Cells Recognize a C-Terminal Ovalbumin 323 – 339 Epitope 1 , 2000 .

[55]  A. Goldberg,et al.  Proteolysis and class I major histocompatibility complex antigen presentation , 1999, Immunological reviews.

[56]  P. Kourilsky,et al.  Role of peptide backbone in T cell recognition. , 1999, Journal of immunology.

[57]  H. Pircher,et al.  Protection against Lymphocytic Choriomeningitis Virus Infection Induced by a Reduced Peptide Bond Analogue of the H-2Db-restricted CD8+ T Cell Epitope GP33* , 1999, The Journal of Biological Chemistry.

[58]  G. Jung,et al.  N‐hydroxy‐amide analogues of MHC‐class I peptide ligands with nanomolar binding affinities , 1998, Journal of peptide science : an official publication of the European Peptide Society.

[59]  T. Walk,et al.  New Synthetic Non-peptide Ligands for Classical Major Histocompatibility Complex Class I Molecules* , 1998, The Journal of Biological Chemistry.

[60]  E. Sercarz,et al.  Modulation of the immunogenicity of antigenic determinants by their flanking residues. , 1998, Immunology today.

[61]  P. A. Peterson,et al.  Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. , 1998, Immunity.

[62]  A. Ménez,et al.  Pseudopeptide ligands for MHC II-restricted T cells. , 1998, International immunology.

[63]  A Sette,et al.  Two complementary methods for predicting peptides binding major histocompatibility complex molecules. , 1997, Journal of molecular biology.

[64]  V. Lotteau,et al.  Selective increased presentation of type II collagen by leupeptin. , 1997, International immunology.

[65]  J. Briand,et al.  Exploration of Requirements for Peptidomimetic Immune Recognition , 1996, The Journal of Biological Chemistry.

[66]  P. Kourilsky,et al.  Efficient Binding of Reduced Peptide Bond Pseudopeptides to Major Histocompatibility Complex Class I Molecule (*) , 1995, The Journal of Biological Chemistry.

[67]  S. Diment,et al.  Destructive proteolysis by cysteine proteases in antigen presentation of ovalbumin , 1995 .

[68]  H. Rammensee,et al.  Chemistry of peptides associated with MHC class I and class II molecules. , 1995, Current opinion in immunology.

[69]  J. Berg,et al.  A comparison of the immunogenicity of a pair of enantiomeric proteins , 1993, Proteins.

[70]  K. Rock,et al.  Two genetically identical antigen-presenting cell clones display heterogeneity in antigen processing. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Alessandro Sette,et al.  Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells , 1987, Nature.

[72]  P. Marrack,et al.  The major histocompatibility complex-restricted antigen receptor on T cells. , 1984, Annual review of immunology.

[73]  P. Marrack,et al.  THE MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTED ANTIGEN RECEPTOR ON T CELLS , 2003 .

[74]  P. Marrack,et al.  Use of I region-restricted, antigen-specific T cell hybridomas to produce idiotypically specific anti-receptor antibodies. , 1983, Journal of immunology.

[75]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.